FDA approves GSK’s Hibsago for chronic hepatitis B

By Public Technologies
  • FDA approved GSK’s Hibsago (bepirovirsen) for chronic hepatitis B in eligible adults without cirrhosis.
  • The six-month treatment is used with nucleos(t)ide analogue therapy, with self-administration available following the first dose.
  • Phase III trials showed a 19% functional cure rate versus 0% with placebo in patients with HBsAg levels ≤3,000 IU/ml.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on October 20, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.